// Chartbeat tag // Chartbeat tag
High-dose flu vaccine about 25% more effective for seniors ... Regular internet use reduces dementia risk in seniors, scientists say ... Expert panel recommends seniors receive Pfizer pneumonia vaccine ... TX lawmakers propose '3 strikes' rule to close nursing homes
Big pharmaceutical companies are exploring "brand personality" in their marketing strategies, according to new research.
Pfizer Inc. said it is planning on presenting the results of its Community-Acquired Pneumonia Immunization Trial in Adults study next month, and that it may have significant impact on preventing community-acquired pneumonia for seniors.
Pfizer must pay $142 million for the marketing and prescribing of epilepsy drug Neurontin for unapproved uses, a federal appeals court has ruled. The justices refused to overturn a jury's previous verdict. The jury determined Pfizer marketed Neurontin for bipolar disorder, migraines and neuropathic pain. The Food and Drug Administration had not approved the medicine for any of those uses.
The experimental drug Eliquis prevented blood clots in the legs and lungs and kept them from recurring, according to a new study. Patients who took the medicine were 81% less likely to have symptoms of a clot or die than those who received a placebo, according to findings published in the New England Journal of Medicine.
Federal regulators recently approved Pfizer's new Xeljanz treatment for rheumatoid arthritis. Xeljanz was approved for patients with moderate to severe rheumatoid arthritis who did not benefit from the oral treatment methotrexate.
Federal regulators approved Pfizer's new Xeljanz treatment for rheumatoid arthritis Tuesday. The potentially lucrative drug is now poised to enter a market that already features Humira, Abbott Laboratories' top-selling rheumatoid arthritis treatment.
The typical long-term care resident requires eight or more medications daily. So with Hurricane Sandy ripping through the pharmaceutical corridor last week, many operators were rightfully concerned about possible medication shortages. The good news is that most drug firms appear to be getting back on their feet quickly
Alzheimer's researchers met with disappointment Monday when officials from Pfizer announced that the experimental drug bapineuzumab failed to improve dementia symptoms in a Phase 3 trial.
Makers of the Alzheimer's drug Aricept released a higher dosage version of the medication despite concerns about side effects and reduced efficacy, a study reports.